Find Funding Opportunities

Purpose. This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, and refine effective and efficient methods, structures, and strategies to disseminate and implement research-tested health behavior change interventions and evidence-based prevention, early detection, diagnostic, treatment, and quality of life improvement services into public health and clinical practice settings. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) award mechanism and runs in parallel with FOAs of identical scientific scope, PAR-10-038 and PAR-10-039, which encourage applications under the NIH Research Project Grant (R01) and NIH Small Grant (R03) award mechanisms. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received.

Purpose. This FOA encourages Research Project Grant (R01) applications proposing to study mechanisms and management of critical illness and injury, including trauma and neurotrauma, in aging. Studies may be mechanistic, observational, or interventional in nature. Secondary analyses of existing datasets, such as from large observational studies or clinical trials, may be proposed. Animal studies are appropriate in cases where human studies are not feasible. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-10-044, that encourages applications under the R21 Exploratory/Developmental grant mechanism, PA-10-043, that encourages applications under the R03 Small Research grant mechanism. This FOA also runs in parallel with an FOA of similar scientific scope, PA-10-045, which encourages applications under the R34 clinical trial planning grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Purpose: The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) to eligible institutions as the primary means of supporting predoctoral and postdoctoral research training to help ensure that a diverse and highly trained workforce is available to assume leadership roles related to the Nations biomedical, behavioral and clinical research agenda. The primary objective of the T32 program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program supports predoctoral and postdoctoral research training programs (including those with short term research training) at domestic institutions of higher education with the T32 funding mechanism. Note that programs solely for short-term research training should not apply to this announcement, but rather the separate (T35) NRSA Short-Term Institutional program exclusively reserved for predoctoral and/or postdoctoral level short-term research training programs (see PA-10-037). Mechanism of Support: This Funding Opportunity Announcement (FOA) will utilize the Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32). Funds Available and Anticipated Number of Awards: Because the nature and scope of the proposed research training will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the number, quality, duration, and costs of the applications received.

Purpose. This FOA issued under the NIH Common Fund solicits grant applications that propose to continue the NIH National Centers for Biomedical Computing (NCBC) program. These Centers, in conjunction with individual investigator awards, are creating a networked effort to build the computational infrastructure for biomedical computing in the nation. The NCBC program is devoted to all facets of biomedical computing, from basic research in computational science to providing the tools and resources that biomedical and behavioral researchers need to do their work. In addition to carrying out fundamental research, it is expected that the NCBC will play a major role in educating and training researchers to engage in biomedical computing. Mechanism of Support. This FOA will utilize the U54 cooperative agreement mechanism. Funds Available and Anticipated Number of Awards. The Common Fund has committed $62M to this program to be distributed over the first 4 years of the program. Participating ICs will provide additional funding for each award, with up to seven Center awards, and will provide 100% of the funding in the final year of the program.

Purpose. This program provides three to five years of mentored career development support to clinically trained faculty members in strong research environments to enable them to gain skills and experience in aging research under the guidance of a mentor or mentors, and to establish an independent program of research in this field. Clinically trained professionals or individuals with a clinical degree who are interested in further career development in biomedical research that is patient-oriented should refer to the Paul B. Beeson Mentored Patient-Oriented Research Development (K23) Award in Aging [AG-10-011].The program also includes an annual meeting that allows opportunities to partner with national mentors and fellow awardees. Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH K08 (Mentored Clinical Scientist Development Award). Funds Available and Anticipated Number of Awards. The FY 2010 anticipated amount is $1 million. The anticipated number of awards is 5 to 7.

Purpose. This program provides three to five years of mentored career development support to clinically trained faculty members in strong research environments who have made a commitment to focus their research endeavors on patient-oriented research. The award will enable them to gain skills and experience in aging research under the guidance of a mentor or mentors, and to establish an independent program of research in this field. Clinically trained professionals or individuals with a clinical degree who are interested in further career development in biomedical research that is not patient-oriented should refer to the Paul B. Beeson Clinical Scientist Career Development Award in Aging (K08) [AG-10-010].The program also includes an annual meeting that allows opportunities to partner with national mentors and fellow awardees. Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the Mentored Patient-Oriented Research Career Development Award (K23) mechanism. Funds Available and Anticipated Number of Awards. The FY 2010 anticipated amount is $1 million. The anticipated number of awards is 5 to 7.

Purpose. This Funding Opportunity Announcement (FOA) requests applications for exploratory/developmental translational research on therapeutics for reducing mortality and morbidity caused by acute exposures to chemical threat agents. Chemical threats include traditional chemical warfare nerve agents such as sarin and VX, toxic industrial chemicals such as cyanide and chlorine, and toxic agricultural chemicals such as parathion and sodium fluoroacetate. Projects supported by this FOA are expected to generate preliminary data that would enable the development of competitive applications for more extensive support from the NIH CounterACT program (see www.ninds.nih.gov/counteract for a description) and other related research and development programs. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

Purpose. Participating Institutes and Centers of the NIH invite applications for R01 awards to support Bioengineering Research Grants (BRGs) for basic and applied multi-disciplinary research that addresses important biological, bioengineering or medical research problems. The BRGs support multi-disciplinary research performed in a single laboratory or by a small number of investigators that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose, or treat disease or to understand health and behavior. A BRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism and runs in parallel with a FOA of similar scientific scope, Exploratory/Developmental Bioengineering Research Grants, PA-10-010, that encourages applications under the R21 mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Purpose. This Funding Opportunity Announcement (FOA) is intended to encourage innovation and high risk/impact bioengineering research in new areas. While minimal or no preliminary data are expected to be described in the application, applications should clearly indicate the significance of the proposed work and that the proposed research and/or development is scientifically sound, that the qualifications of the investigators are appropriate, and that resources available to the investigators are adequate. An EBRG application may propose hypothesis-driven, discovery-driven, developmental, or design-directed research. The research proposed under this program can explore approaches and concepts new to a particular substantive area; research and development of new technologies, techniques or methods; or initial research and development of data upon which significant future research may be built. Mechanism of Support. This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with a FOA of similar scientific scope, PA-10-009 Bioengineering Research Grants, and PAR-07-352, Bioengineering Research Partnerships. Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

Purpose. The National Institute of Neurological Disorders and Stroke (NINDS) invites new and competing renewal applications for the Morris K. Udall Centers of Excellence for Parkinsons Disease Research program. Proposed Centers must involve multidisciplinary teams engaged in integrative basic, translational and clinical research on Parkinsons disease (PD), with the primary objective of transforming this research into the development of new treatments. Investigations on related parkinsonian disorders may be included, to the extent that these inform and/or expand research on PD. Accomplishment of the stated goals of the Center, and of each project, must require substantial collaborative efforts and the utilization of common resource cores. All proposed Centers must include a pre-clinical and/or clinical translational research project. In this context, pre-clinical translation is defined as pre-IND/IDE (Investigational New Drug/Investigational Device Exemption) stage research on potential therapeutic or diagnostic candidates. Clinical translational projects are early-stage projects in human subjects that are designed as first steps toward transformation of scientific discoveries arising from basic research, clinical research or population studies into new modalities for the prevention, treatment and cure of PD. All Centers are required to have an Administrative Core; inclusion of other research and core components is flexible within stated budget limits. Inclusion of a clinical component, a clinical translational research project plus a clinical resource core, is encouraged, as is emphasis on training and public outreach activities. The Udall Center Director (PI) must be an established leader in scientific research with visionary leadership skills and proven expertise in research project and personnel management. Eligible institutions must demonstrate commitment to and support for the establishment and continuation of the proposed Udall Center. Successful applicants will participate in a network of existing Udall Centers to foster the translation of new scientific findings and technological developments into novel treatments for PD.